Quality of Life in New Treatable Therapy as Rabeprazole Option for Refractory Reflux Esophagitis

Eisai

Status: Completed

Conditions: Refractory Reflux Esophagitis

Treatments: Drug: rabeprazole sodium

Study type: Observational

Funder types: Industry

Identifiers

NCT01321567

PRT11T

Details and patient eligibility

About

To investigate the efficacy and safety of PARIET twice daily (b.i.d.) in patients with Proton Pump Inhibitor-resistant reflux esophagitis

Enrollment: 2,157 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion criteria;

-Proton pump inhibitor-resistant reflux esophagitis. (Patients who have mucosal breaks (erosions, ulcers) on endoscopy)

Exclusion criteria;

• Patients with a history of hypersensitivity to any ingredients of PARIET.
• Patients on atazanavir sulfate.

Trial design

2,157 participants in 1 patient group

Rabeprazole Sodium

Treatment:

Drug: rabeprazole sodium